OBJECTIVE： To observe the effects of nimodipine on peripheral facial paralysis and hearing in mimetic convulsion patients after microvascular decompression. METHODS： 162 mimetic convulsion patients underwent microvascular decompression were enrolled in this study， and then randomly divided into control group and observation group， 81 cases in each group. Control group was given routine microvascular decompression， and observation group was additionally given intravenous pump of Nimodipine injection 40 mg，qd，2 mg/h for consecutive 3 days after operation， and then given Nimodipine tablet 40 mg， qd， for 10 days. The incidence of peripheral facial paralysis and hearing disorder， onset time， duration time and severity of facial paralysis were observed in 2 groups. RESULTS： The incidence of peripheral facial paralysis and hearing disorder were 8.6％ and 6.2％ in observation group， which were significantly lower than 14.8％ and 11.1％ of control group， with statistical significance （P＜0.05）. The onset and duration time of peripheral facial paralysis was （15.32±3.15） d and （36.52±5.84） d in observation group， which were significantly later and lower than （12.21±2.16） d and （44.73±6.57） d of control group， with statistical significance （P＜0.05）. According to House-Brackman classification method， the incidence of Ⅲ、Ⅳ facial paralysis was lower in control group than that in observation group， with statistical significance （P＜0.05）. CONCLUSIONS： Nimodipine can significantly decrease the incidence of peripheral facial paralysis and hearing disorder in mimetic convulsion patients after microvascular decompression， and contributes to the recovery of injured nerve function.